Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.33 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6082635 | 0.88 | IDH2 (0.42) | CRHR1IDH2 | |
| SCHEMBL6082630 | 0.88 | IDH2 (0.42) | CRHR1IDH2 | |
| SCHEMBL6082842 | 0.84 | IDH2 (0.39) | MDM2CRHR1IDH2 | |
| SCHEMBL6082839 | 0.84 | IDH2 (0.39) | MDM2CRHR1IDH2 | |
| SCHEMBL6082517 | 0.82 | KDM4E (0.37) | CRHR1FFAR4TP53 | |
| SCHEMBL6082522 | 0.82 | KDM4E (0.37) | CRHR1FFAR4TP53 | |
| SCHEMBL6818769 | 0.79 | FFAR4 (0.35) | CRHR1FFAR4 | |
| SCHEMBL6082274 | 0.77 | CRHR1 (0.38) | MDM2CRHR1FFAR4 | |
| SCHEMBL6082269 | 0.77 | CRHR1 (0.38) | MDM2CRHR1FFAR4 | |
| SCHEMBL6082541 | 0.70 | CRHR1 (0.42) | CRHR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067658-B2 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004031189-A1 | PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | CRHR1, CRHR2, CRH | MDM2 4254/4885CRHR1 1/4885FFAR4 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.